Free Newsletter
Daiichi aims for 60 percent growth
Daiichi Sankyo says it's ready for it's close-up. The company got FDA approval last week for a combo remedy for hypertension, Azor, and now it's meeting with its Congressman to talk about adding new jobs at its New Jersey HQ. Perhaps most surprising is its sales-growth target: a whopping 60 percent over the next three years, based on its hopes for Azor and two other meds coming up the pipeline.
Not exactly a household name in the U.S., Daiichi Sankyo has historically developed drugs for licensing to other companies, including Pravachol, a statin sold by Bristol-Myers Squibb; and Levaquin, an antibiotic marketed by Johnson & Johnson. Now, to do more marketing on its own, Daiichi Sankyo has more than doubled its sales force. They'll have to hoof it to meet that ambitious growth target.
- check out Daiichi Sankyo's press release
- read the article in PharmaTimes
Related Articles:
Daiichi Sankyo buys OTC business. Report
Daiichi Sankyo invests in venture fund. Report
Big Pharma brings home the cash, slices payroll. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: